(3S)-1-(2-甲氧基乙基)-3-吡咯烷胺 | 216667-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (3S)-1-(2-甲氧基乙基)-3-吡咯烷胺
• 英文名称: (S)-1-(2-methoxyethyl)-3-aminopyrrolidine
• 英文别名: (S)-1-(2-Methoxyethyl)pyrrolidin-3-amine；(3S)-1-(2-methoxyethyl)pyrrolidin-3-amine
• CAS: 216667-74-2
• 化学式: C₇H₁₆N₂O
• 分子量: 144.217
• InChiKey: SRWRVWNAMHIATJ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S)-1-(2-甲氧基乙基)-3-吡咯烷胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.0h， 生成 (S)-1-(2-methoxyethyl)-3-(cyclohexylamino)pyrrolidine
  参考文献：
  名称：

  Structure-Selectivity Relationship in Alkyllithium−Aldehyde Condensations Using 3-Aminopyrrolidine Lithium Amides as Chiral Auxiliaries

  摘要：

  A nonracemizing route to a set of chiral 3-aminopyrrolidines, based on 4-hydroxy-(L)-proline, is described. The induction potential of the lithium amides derived from these diamines has then been investigated in the asymmetric addition of alkyllithium compounds onto various aldehydes. Enantiomeric excesses up to 76% have been obtained in the case of the condensation of n-butyllithium onto o-tolualdehyde under standard experimental conditions (THF, -78 degrees C). Interestingly, the presence of a second asymmetric center, such as an alpha-methylbenzyl group, on the lateral 3-amino group gives access, according to its configuration, to one or the other of the 1-o-tolylpentan-1-ol enantiomers.

  DOI：

  10.1021/jo9810260
• 作为产物：
  描述：

  (3R)-1-(2-甲氧基乙基)-3-吡咯烷醇 在 lithium aluminium tetrahydride 、 迭氮酸 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 乙醚 、 苯 为溶剂， 反应 8.0h， 生成 (3S)-1-(2-甲氧基乙基)-3-吡咯烷胺
  参考文献：
  名称：

  Structure-Selectivity Relationship in Alkyllithium−Aldehyde Condensations Using 3-Aminopyrrolidine Lithium Amides as Chiral Auxiliaries

  摘要：

  A nonracemizing route to a set of chiral 3-aminopyrrolidines, based on 4-hydroxy-(L)-proline, is described. The induction potential of the lithium amides derived from these diamines has then been investigated in the asymmetric addition of alkyllithium compounds onto various aldehydes. Enantiomeric excesses up to 76% have been obtained in the case of the condensation of n-butyllithium onto o-tolualdehyde under standard experimental conditions (THF, -78 degrees C). Interestingly, the presence of a second asymmetric center, such as an alpha-methylbenzyl group, on the lateral 3-amino group gives access, according to its configuration, to one or the other of the 1-o-tolylpentan-1-ol enantiomers.

  DOI：

  10.1021/jo9810260

文献信息

• Kinase inhibitor compounds
  申请人：Liang Congxin

  公开号：US20090076005A1

  公开（公告）日：2009-03-19

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

  这项发明涉及化合物、包含这些化合物的组合物，以及使用这些化合物和化合物组合物的方法。本文描述的化合物、组合物和方法可用于治疗激酶介导的过程，并治疗疾病和疾病症状，特别是那些由特定激酶酶介导的症状。
• KINASE INHIBITOR COMPOUNDS
  申请人：Liang Congxin

  公开号：US20120115866A1

  公开（公告）日：2012-05-10

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

  本发明涉及化合物、含有这些化合物的组合物以及使用这些化合物和组合物的方法。本文所描述的化合物、组合物和方法可用于治疗激酶介导的过程，以及治疗疾病和疾病症状，特别是那些由某些激酶酶介导的疾病和疾病症状的治疗。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• Cannabinoid receptor modulators
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US11214548B2

  公开（公告）日：2022-01-04

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些调节大麻素 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明还涉及某些能调节 CB1 受体和 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明的化合物及其药物组合物用于治疗以下疾病的方法：疼痛，例如骨痛和关节痛、肌肉痛、牙痛、偏头痛和其他头痛、炎症性疼痛、神经性疼痛、作为治疗药物的不良反应出现的疼痛以及与骨关节炎相关的疼痛；痛觉减退；异动症；炎症性痛觉减退；神经性痛觉减退；急性痛觉；骨质疏松症；多发性硬化症相关的痉挛、自身免疫性疾病、过敏反应、中枢神经系统炎症、动脉粥样硬化、不想要的免疫细胞活性和炎症、老年性黄斑变性、咳嗽、白血病、淋巴瘤、中枢神经系统肿瘤、前列腺癌、阿尔茨海默病、中风引起的损伤、痴呆、肌萎缩性脊髓侧索硬化症和帕金森病。
• [EN] METHOD FOR PREPARING PYRROLIDINYL UREA DERIVATIVE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉ DE PYRROLIDINYL-URÉE<br/>[ZH] 吡咯烷基脲衍生物的制备方法
  申请人：ZHANGZHOU PIEN TZE HUANG PHARM

  公开号：WO2021139795A1

  公开（公告）日：2021-07-15

  本发明公开了一种作为TrkA抑制剂的吡咯烷基脲衍生物的制备方法，还公开了式(I)化合物的中间体化合物及其制备方法。